Glycosylation products in prostate diseases

Silva, Priscila Marcelino dos Santos; Albuquerque, Priscilla Barbosa Sales de; Oliveira, Weslley Felix de; Coelho, Luana Cassandra Breitenbach Barroso; Correia, Maria T.S.

doi:10.1016/j.cca.2019.08.003

Cited by 10 publications

(4 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSA is an organ-specific glycoprotein, secreted by the epithelium and periurethral glands. PSA occurs as a 237-amino acid serine protease with chymotrypsinlike activity, and its transcription is regulated by androgens [41,42]. PSA is secreted as an inactive proenzyme (proPSA) into seminal fluid, which during the liquefaction process is converted by kallikrein-related peptidase 2 to a 33 kDa mature active form [3,43,44].…”

Section: Biology Of Prostate-specific Antigenmentioning

confidence: 99%

“…In the early stage of prostate cancer development, disruption of the basal cell layer and the basement membrane of the prostate epithelium results in leakage of PSA into the peripheral circulation, and this circulating blood form of PSA is identified in the early detection tests for prostate cancer [3]. The serum PSA level increases with the clinical severity of disease and is proportional to tumor volume, whereas after radical prostatectomy its level in serum reaches undetectable values [41,45]. Schroeder et al showed that PSA-based screening of prostate cancer reduced the rate of death by 20% but simultaneously was correlated with a high degree of overdiagnosis [46].…”

Section: Biology Of Prostate-specific Antigenmentioning

confidence: 99%

See 1 more Smart Citation

Glycosylation: Rising Potential for Prostate Cancer Evaluation

Kałuża

Szczykutowicz

Ferens-Sieczkowska

2021

Cancers

View full text Add to dashboard Cite

Prostate cancer is the second most commonly diagnosed cancer among men. Alterations in protein glycosylation are confirmed to be a reliable hallmark of cancer. Prostate-specific antigen is the biomarker that is used most frequently for prostate cancer detection, although its lack of sensitivity and specificity results in many unnecessary biopsies. A wide range of glycosylation alterations in prostate cancer cells, including increased sialylation and fucosylation, can modify protein function and play a crucial role in many important biological processes in cancer, including cell signalling, adhesion, migration, and cellular metabolism. In this review, we summarize studies evaluating the prostate cancer associated glycosylation related alterations in sialylation, mainly α2,3-sialylation, core fucosylation, branched N-glycans, LacdiNAc group and presence of truncated O-glycans (sTn, sT antigen). Finally, we discuss the great potential to make use of glycans as diagnostic and prognostic biomarkers for prostate cancer.

show abstract

Section: Biology Of Prostate-specific Antigenmentioning

confidence: 99%

Section: Biology Of Prostate-specific Antigenmentioning

confidence: 99%

Glycosylation: Rising Potential for Prostate Cancer Evaluation

Kałuża

Szczykutowicz

Ferens-Sieczkowska

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…PCa has cPSA values that are much higher than those of patients with BPH [11,12]. However, serum cPSA provides signi cant information for PCa staging and differentiation between PCa and BPH [13,14].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic efficiency of calculated complex prostate-specific antigen percentage (cPSA%) for prostate cancer and benign prostate hyperplasia

Omer,

Ismail,

Altayb

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Serum cPSA% provides evidence for prostate cancer (PCa) staging and differential diagnosis from benign prostatic hyperplasia (BPH). This study examined the effectiveness of the calculated cPSA% as a diagnostic and prognostic marker for PCa and to differentiate between PCa and BPH. Methods In a case-control study, serum total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) were measured in newly diagnosed PCa and BPH patients. The cPSA% and fPSA% were calculated. The sensitivity and specificity of the tPSA-faction isoforms were analyzed and evaluated in the study groups. Results In PCa, the average cPSA% was significantly higher and fPSA% was lower (86.0 ± 30.4% and 14.0 ± 3.50%, p < 0.001). In the all levels of tPSA, cPSA showed the highest sensitivity and fPSA higher specificity (69%, AUC: 0.723, and 72%, AUC: 0.253). In the tPSA range of 4–10 ng/ml, cPSA% and fPSA% have similar efficiency, whereas, at 10–50 ng/ml, cPSA noticed higher efficiency than fPSA (92%, AUC: 0.549 and 51%, AUC: 0.369). Conclusion The cPSA achieves the requirements of PCa biomarkers and has greater efficiency for the diagnosis of PCa and differentiating it from BPH in gray-zone and late stages.

show abstract

“…Several new prognostic markers, including the clinicopathological status and liquid biopsy (such as circulating tumor cell and cell-free DNA) have been investigated in CRPC 10–13 . Of those, several biomarkers for CRPC using serum glycans have been reported to date 14–16 . More than half of the proteins have glycans and glycans play crucial roles in molecular interactions and signal transduction 17 .…”

Section: Introductionmentioning

confidence: 99%

Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer

Matsumoto

Hatakeyama

Yoneyama

et al. 2019

Sci Rep

View full text Add to dashboard Cite

We investigated the diagnostic and prognostic potential of serum N-glycan profiling for castrationresistant prostate cancer (CRPC). We retrospectively investigated serum N-glycan structural analysis by glycoblotting for 287 patients with benign prostatic hyperplasia (BPH), 289 patients with newly diagnosed prostate cancer (PC), 57 patients with PC treated with androgen-deprivation therapy without disease progression (PC-ADT), and 60 patients with CRPC. N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The CRPC N-glycan score could classify CRPC patients with sensitivity, specificity, and area under the curve of 87%, 69%, and 0.88, respectively. the cRpc N-glycan score >1.7 points was significantly associated with poor prognosis in patients with CRPC. The glycoprotein analysis showed that not immunoglobulins but α-1-acid glycoprotein (AGP) were a potential candidate for the carrier protein of N-glycans. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC. Prostate cancer(PC) has been increasing worldwide and major cancer in Japan in recent years 1. Although prostate-specific antigen (PSA) is a useful biomarker for PC detection 2-4 , the utility of PSA for castration-resistant PC (CRPC) is insufficient 5-9. Several new prognostic markers, including the clinicopathological status and liquid biopsy (such as circulating tumor cell and cell-free DNA) have been investigated in CRPC 10-13. Of those, several biomarkers for CRPC using serum glycans have been reported to date 14-16. More than half of the proteins have glycans and glycans play crucial roles in molecular interactions and signal transduction 17. As glycosylation for proteins and lipids was tightly controlled by glycosyltransferases, malfunction of the glycan system is related to several diseases and cancers 18-25. Although cancer-associated glycan alterations represent potential cancer biomarkers, it has not been applied clinically because of the complicated protocols and the analytical methods involved. A new approach that combines chemoselective N-glycan enrichment (glycoblotting methods) and quantitative N-glycan mass spectrometry improved N-glycan analysis 26. Our previous studies suggested that a quantitative N-glycan analysis is a promising approach for biomarker screening in several cancers 14,21,27-30. Among these studies, a few evaluated the potential diagnostic value of serum N-glycomics (tri-and tetra-antennary N-glycans) in patients with CRPC 14,21,30. In the present study, we evaluated the diagnostic and prognostic potential of serum N-glycan profiling for CRPC using a combination of serum N-glycans. Results Table 1 summar...

show abstract

Glycosylation products in prostate diseases

Cited by 10 publications

References 86 publications

Glycosylation: Rising Potential for Prostate Cancer Evaluation

Glycosylation: Rising Potential for Prostate Cancer Evaluation

Diagnostic and prognostic efficiency of calculated complex prostate-specific antigen percentage (cPSA%) for prostate cancer and benign prostate hyperplasia

Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer

Contact Info

Product

Resources

About